If you would like to receive further information on the National Innovation and Science Agenda, please subscribe to our email updates.
First BTF investment aims to improve lives through innovationSaturday, May 27, 2017
The development of a promising new treatment for peanut allergy in children will be the first project to receive $10 million in funding from the Australian Government’s Biomedical Translation Fund (BTF).
The BTF combines $250 million of Commonwealth funding to be at least matched by private capital secured by independent licensed fund managers to realise a substantial $500 million fund.
The first investment from OneVentures Healthcare Fund III will provide $10 million to Prota Therapeutics to advance the development of a promising new treatment for peanut allergies in children.
The oral immunotherapy treatment is a world-first approach aimed at treating a range of food allergies. The first product is for the treatment of life threatening peanut allergy – a leading cause of death from food allergies.
Read the media release.
Find more information on the Biomedical Translation Fund.